ArticleScientific reports2026
Evaluation of serum progranulin as a biomarker for early detection of neonatal sepsis in a microbiological context.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal sepsis remains a major contributor to neonatal morbidity and mortality worldwide. The nonspecific nature of clinical signs and the limited sensitivity of conventional microbiological methods, such as blood culture, often hinder early diagnosis. This study evaluated the diagnostic performance of serum progranulin (PGRN) in comparison with established biomarkers-procalcitonin (PCT) and C-reactive protein (CRP)-in the early detection of suspected neonatal sepsis before microbiological confirmation, thereby supporting prompt clinical decision-making.
methodsA total of 60 neonates with clinically suspected sepsis and 30 healthy controls were enrolled. Before initiation of antimicrobial therapy, blood samples were collected for microbiological culture, complete blood count, and platelet count. Additional samples were analyzed for CRP, PCT, and PGRN levels using enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy was determined using receiver operating characteristic (ROC) curve analysis.
resultsSerum PGRN levels were significantly elevated in the sepsis group compared to controls (77.26 vs. 28.78 ng/mL; Mann-Whitney p < 0.001). PGRN demonstrated excellent diagnostic accuracy (AUC = 0.986; 95% CI 0.957-1.000; p < 0.001), outperforming both PCT (AUC = 0.772; 95% CI 0.666-0.877; p < 0.001) and CRP (AUC = 0.833; 95% CI 0.752-0.915; p < 0.001). At a cut-off of 35.80 ng/mL, PGRN yielded a sensitivity of 98.31% and a negative predictive value of 96.7%. Combined assessment of PGRN and PCT further enhanced diagnostic sensitivity and specificity.
conclusionSerum progranulin is a promising biomarker for the early diagnosis of neonatal sepsis and demonstrates superior diagnostic accuracy compared to PCT and CRP. When integrated with conventional microbiological testing and PCT measurement, PGRN can substantially improve early detection rates, enable timely therapeutic intervention, and potentially reduce sepsis-related mortality in neonates.
Indexed as
Identifiers
42151335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.